Affordable Access

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Authors
  • Hutson, Thomas E
  • Molto, Luis
  • Mekhail, Tarek
  • Elson, Paul
  • Finke, James
  • Tannenbaum, Charles
  • Borden, Ernest
  • Dreicer, Robert
  • Olencki, Thomas
  • Bukowski, Ronald M
Type
Published Article
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Publication Date
Apr 01, 2003
Volume
9
Issue
4
Pages
1354–1360
Identifiers
PMID: 12684404
Source
Medline
License
Unknown

Abstract

CIFN was safely administered s.c. three times weekly at doses up to 15.0 microg/m(2). Although there were no responses, the median survival was longer than expected in a previously treated patient population with metastatic RCC.

Report this publication

Statistics

Seen <100 times